September 25, 2024

NEJM: Results From Targeted Therapy for Ulcerative Colitis Study – Cedars-Sinai

September 25, 2024

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis – NEJM

September 25, 2024

Patients With Moderate-to-Severe Ulcerative Colitis May Find Significant Relief as New Treatment Option Shows Good Results in Clinical Trial – Mount Sinai

September 20, 2024

Ulcerative Colitis Diarrhea: Symptoms, Causes, Treatment – HealthCentral

September 17, 2024

UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval – UChicago Medicine